Compare IIIN & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IIIN | FLGT |
|---|---|---|
| Founded | 1953 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 739.2M | 867.4M |
| IPO Year | 1994 | 2016 |
| Metric | IIIN | FLGT |
|---|---|---|
| Price | $30.57 | $15.64 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $28.33 |
| AVG Volume (30 Days) | 103.2K | ★ 760.3K |
| Earning Date | 04-16-2026 | 05-01-2026 |
| Dividend Yield | ★ 3.59% | N/A |
| EPS Growth | ★ 112.12 | N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $647,706,000.00 | $18,730,000.00 |
| Revenue This Year | $14.20 | $10.66 |
| Revenue Next Year | $6.82 | $12.17 |
| P/E Ratio | $80.13 | ★ N/A |
| Revenue Growth | ★ 22.39 | N/A |
| 52 Week Low | $22.49 | $13.46 |
| 52 Week High | $41.64 | $31.04 |
| Indicator | IIIN | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 28.19 | 34.09 |
| Support Level | $30.23 | $13.46 |
| Resistance Level | $32.50 | $22.48 |
| Average True Range (ATR) | 1.06 | 0.64 |
| MACD | -0.44 | 0.37 |
| Stochastic Oscillator | 8.18 | 91.86 |
Insteel Industries Inc produces and sells prestressed concrete strand (PC strand) and welded wire reinforcement (WWR). PC strand, a high-strength seven-wire cable, is used to strengthen precast concrete in structures like bridges, parking decks, and buildings, enabling longer spans and slimmer designs. WWR includes engineered structural mesh for primary reinforcement, concrete pipe reinforcement for drainage and sewage systems, and standard WWR for crack control in residential and light commercial construction. The company serves markets in the United States and internationally, with the majority of revenue generated in the United States.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.